Stockscreener 앱 받기
134.27
0.94%
1.25
시장 영업 전:
134.04
-0.23
-0.17%
전일 마감가:
$133.02
열려 있는:
$132.81
하루 거래량:
6.65M
Relative Volume:
1.08
시가총액:
$233.69B
수익:
$43.11B
순이익/손실:
$13.94B
주가수익비율:
16.79
EPS:
7.9963
순현금흐름:
$6.78B
1주 성능:
+0.60%
1개월 성능:
+1.57%
6개월 성능:
+8.33%
1년 성능:
+17.13%
1일 변동 폭
$132.17
$134.72
1주일 범위
$130.51
$135.37
52주 변동 폭
$110.86
$140.84
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
134.27 | 231.52B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
SYK
Stryker Corp
|
375.29 | 141.16B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
BSX
Boston Scientific Corp
|
96.79 | 142.10B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
MDT
Medtronic Plc
|
97.87 | 126.13B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
75.74 | 45.04B | 5.69B | 1.41B | 577.90M | 6.9828 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott Laboratories: There May Be A Surge Coming Next Week (Earnings Preview) (ABT) - Seeking Alpha
First Merchants Corp Sells 4,988 Shares of Abbott Laboratories $ABT - MarketBeat
Maryland State Retirement & Pension System Has $11.45 Million Position in Abbott Laboratories $ABT - MarketBeat
Fluent Financial LLC Has $4.34 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Bleeding Disorder Diagnostics Market Global Forecast 2025-2032: Key Opportunities Through Digital Integration, AI-driven Analytics, and Expanded Point-of-care Testing - GlobeNewswire Inc.
Kingswood Wealth Advisors LLC Has $1.12 Million Holdings in Abbott Laboratories $ABT - MarketBeat
How Abbott Laboratories stock compares to growth peersJuly 2025 Snapshot & Stock Portfolio Risk Control - newser.com
Abbott Labs Is UBS’s Top MedTech Value Play For Growth - Finimize
Abbott Laboratories (NYSE:ABT) Given "Buy (B)" Rating at Weiss Ratings - MarketBeat
UBS reiterates Buy rating on Abbott Labs stock, citing undervalued growth - Investing.com
Puzo Michael J Trims Stake in Abbott Laboratories $ABT - MarketBeat
WoodTrust Financial Corp Acquires 8,165 Shares of Abbott Laboratories $ABT - MarketBeat
Triasima Portfolio Management inc. Buys New Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT is Hendley & Co. Inc.'s 5th Largest Position - MarketBeat
Abbott Laboratories $ABT Shares Sold by NBT Bank N A NY - MarketBeat
Somerville Kurt F Has $21.58 Million Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by BankPlus Trust Department - MarketBeat
SteelPeak Wealth LLC Increases Position in Abbott Laboratories $ABT - MarketBeat
Knights of Columbus Asset Advisors LLC Takes $329,000 Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (ABT): A Healthcare Leader Powering the List of Profitable Dividend Stocks - Yahoo Finance
Abbott Laboratories (ABT) Projected to Post Earnings on Wednesday - MarketBeat
2 Cash-Producing Stocks Worth Your Attention and 1 We Avoid - TradingView
The Bull Case For Abbott Laboratories (ABT) Could Change Following Health Canada Approval of Dissolvable Stent - simplywall.st
Vijay Kumar of Evercore ISI Group Maintains Outperform Rating fo - GuruFocus
Evercore ISI Adjusts Abbott Laboratories Price Target to $144 From $140, Maintains Outperform Rating - MarketScreener
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Abbott Laboratories' (NYSE:ABT) Returns On Capital Are Heading Higher - Yahoo
The Zacks Analyst Blog Highlights Advanced Micro Devices, Abbott Laboratories and Micron Technology - Zacks Investment Research
Global Assets Advisory LLC Trims Holdings in Abbott Laboratories $ABT - MarketBeat
Merit Financial Group LLC Purchases 6,900 Shares of Abbott Laboratories $ABT - MarketBeat
Precision Trading with Abbott Laboratories (ABT) Risk Zones - news.stocktradersdaily.com
Is Abbott Laboratories (ABL) stock positioned for secular growthPortfolio Update Summary & Low Drawdown Trading Strategies - newser.com
What candlestick patterns are forming on Abbott LaboratoriesMarket Risk Analysis & Risk Controlled Swing Alerts - newser.com
Penobscot Investment Management Company Inc. Decreases Stake in Abbott Laboratories $ABT - MarketBeat
Ameriflex Group Inc. Lowers Stock Position in Abbott Laboratories $ABT - MarketBeat
Stock Yards Bank & Trust Co. Reduces Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Top Stock Reports for AMD, Abbott & Micron Technology - The Globe and Mail
Abbott (ABT) Laps the Stock Market: Here's Why - Yahoo Finance
Abbott Laboratories (ABT): Exploring Valuation as Steady Gains Draw Investor Interest in 2024 - simplywall.st
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True? - Yahoo
‘Few missions more meaningful than improving global health,’ says HR expert - Silicon Republic
14,730 Shares in Abbott Laboratories $ABT Purchased by Hilltop National Bank - MarketBeat
Abbott Laboratories $ABT Shares Sold by Lbp Am Sa - MarketBeat
Why analysts recommend Abbott Laboratories (ABL) stockJuly 2025 Breakouts & Long-Term Safe Investment Ideas - newser.com
Ready To Pass On Abbott Laboratories (NYSE:ABT)? Think Again - 富途牛牛
Northstar Group Inc. Acquires 8,255 Shares of Abbott Laboratories $ABT - MarketBeat
Goldman Sachs Maintains Abbott Laboratories(ABT.US) With Buy Rating - 富途牛牛
Abbott Laboratories (ABT) Maintains Strong MedTech Growth Outlook - Insider Monkey
2 Profitable Stocks to Consider Right Now and 1 We Find Risky - FinancialContent
Abbott Laboratories Q3 Earnings Preview: Profit boost expected - MSN
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.64%
0.47%
자본화:
|
볼륨(24시간):